T63313 |
Unecritinib
|
1418026-92-2
|
98%
|
|
Unecritinib (TQ-B3101) is a potent, orally active, highly potent, blood-brain barrier permeable and low toxic inhibitor of EGFR tyrosine kinase with antitumor ac...
|
T77437 |
Telisotuzumab
|
1781223-80-0
|
98%
|
|
Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisot...
|
T3512 |
S49076 HCl
|
1265966-31-1
|
98%
|
|
S49076 is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3. S49076 potently blocked cellular phosphorylation of MET, AXL, and FGFRs and inhibited downstream...
|
T12417 |
PF-04217903 methanesulfonate
|
956906-93-7
|
98%
|
|
PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).
|
T10653 |
C-met-IN-1
|
2084836-84-8
|
98%
|
|
c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.
|
T17184 |
Tyrosine kinase inhibitor
|
1021950-26-4
|
98%
|
|
Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.
|
T15383 |
Glesatinib hydrochloride
|
1123838-51-6
|
98%
|
|
Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO. Glesatinib hydrochloride is also a tyrosine kinase inhibitor. It antagonizes P...
|
T10654 |
C-Met-IN-2
|
1635406-73-3
|
98%
|
|
c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.
|
T12418 |
PF-04217903 phenolsulfonate
|
1159490-85-3
|
98%
|
|
PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).
|
T15384 |
Glesatinib
|
936694-12-1
|
98%
|
|
Glesatinib is an orally active and potent dual inhibitor of MET/SMO. Glesatinib is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multi...
|
TN4474 |
Macrocarpal B
|
142698-60-0
|
98%
|
|
The intestinal absorption of M-A, Macrocarpal B, and Cy-C was passive diffusion as the dominating process and Cy-C was partly ATP-dependent.
|
T6117 |
Tivantinib
|
905854-02-6
|
98%
|
|
Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.
|
T2894 |
Norcantharidin
|
5442-12-6
|
98%
|
|
Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
|
T8825 |
Capmatinib 2HCl.H2O
|
1865733-40-9
|
98%
|
|
Capmatinib 2HCl.H2O is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
|
T25492 |
Hepln-13
|
64369-13-7
|
98%
|
|
Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
|
T5349 |
SCR-1481B1
|
1174161-86-4
|
98%
|
|
SCR-1481B1 has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor
|
T3209 |
AMG-337
|
1173699-31-4
|
98%
|
|
AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).
|
T2419 |
BMS-794833
|
1174046-72-0
|
98%
|
|
BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.
|
TQ0041 |
Ningetinib Tosylate
|
1394820-77-9
|
98%
|
|
Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
|
T1963 |
Capmatinib
|
1029712-80-8
|
98%
|
|
Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
|